NICE Issues Final Guidance on Cimzia for Plaque Psoriasis
NICE has finalized guidance on UCB’s Cimzia (certolizumab pegol), recommending the prescription biologic for treating severe plaque psoriasis.
The institute said it recommends the medication for treating severe plaque psoriasis 1 in adults who haven’t responded to or cannot use other treatments. The drug works to prevent inflammation that can stem from an overactive immune system.
The guidance also noted NICE’s recommendation for the medicine as an additional treatment option for women before or during pregnancy, as well as women who are breastfeeding.